Pure Global
NCT06319482

The Adherence of Proactive Sleep Apnea Therapy

Evaluating and Comparing the Adherence of Proactive Management Therapy for Sleep Apnea
NovaResp Technologies Inc·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Obstructive Sleep Apnea
Drug/Device/Intervention
Proactive CPAP Therapy
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
NovaResp Technologies Inc
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2024
End date
Aug 01, 2025
Enrollment
200 participants
Primary outcome

Adherence

Summary

The goal of this clinical trial is to compare the adherence to Positive Airway Pressure (PAP)
 therapy for newly diagnosed Obstructive Sleep Apnea (OSA) patients. The main question(s) it
 aims to answer are:
 
 1. To compare the adherence of proactive therapy and conventional Automatic-PAP (APAP)
 therapy short-term (3 months) and long-term (12 months) for newly diagnosed OSA
 patients.
 
 2. To compare health outcomes (AHI, nightly pressure, and patient-reported outcomes)
 between proactive therapy and conventional APAP therapy.

ICD-10 classifications
Sleep apnoeaSleep disordersSleep disorder, unspecifiedPrimary sleep apnoea of newbornNonorganic sleep disorders
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06319482
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06319482 through Pure Global AI's free database. This phase not specified trial is sponsored by NovaResp Technologies Inc and is currently Not yet recruiting. The study focuses on Obstructive Sleep Apnea. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.